<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-three patients with primary salivary gland <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were diagnosed between 1990 and 2001 </plain></SENT>
<SENT sid="1" pm="."><plain>The sites of involvement were the parotid gland in 13, the submandibular gland in 9 and the minor salivary gland in 1 </plain></SENT>
<SENT sid="2" pm="."><plain>The sites of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> involvement beyond the salivary glands were the cervical lymph nodes in 7, bone marrow in 3, the axillary lymph nodes in 3, the nasopharynx in 2, the abdominal lymph nodes in 2, the palate, the subconjunctiva, and the spleen in 1 each patient </plain></SENT>
<SENT sid="3" pm="."><plain>Histologically, 19 patients had <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of mucosa-associated lymphoid tissue (MALT) with myoepithelial <z:mp ids='MP_0001870'>sialadenitis</z:mp> in 13, 3 patients had diffuse large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 1 had follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Six patients were in stage I, 4 in II, 1 in III and 12 in IV </plain></SENT>
<SENT sid="5" pm="."><plain>Eight of 23 patients (35%) had <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> before or after the diagnosis of NHL and <z:hpo ids='HP_0000001'>all</z:hpo> suffered from MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Four patients with parotid MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo> had primary or <z:e sem="disease" ids="C0151450" disease_type="Disease or Syndrome" abbrv="">secondary Sjogren's syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>One each patient suffered from <z:hpo ids='HP_0000836'>hyperthyroidism</z:hpo>, <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, <z:hpo ids='HP_0000793'>membranoproliferative glomerulonephritis</z:hpo> and <z:hpo ids='HP_0100778'>cryoglobulinemia</z:hpo>, respectively </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the 6 stage I patients had achieved complete remission (CR) without relapses 17-84 months (median 44 months) after treatment </plain></SENT>
<SENT sid="9" pm="."><plain>Excluding a stage IV patient with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who died at 3.5 months without treatment, CR was achieved in <z:hpo ids='HP_0000001'>all</z:hpo> of the remaining 16 patients </plain></SENT>
<SENT sid="10" pm="."><plain>However, a high relapse rate (9/16, 56%) was noted in stage II-IV patients </plain></SENT>
<SENT sid="11" pm="."><plain>These patients tended to relapse in the original sites, but achieved CR again after chemotherapy or radiotherapy </plain></SENT>
<SENT sid="12" pm="."><plain>One patient with MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo> developed histologic transformation into diffuse large <z:hpo ids='HP_0002665'>lymphoma</z:hpo> during relapse and died of refractory disease </plain></SENT>
<SENT sid="13" pm="."><plain>Overall, only 2 patients succumbed </plain></SENT>
<SENT sid="14" pm="."><plain>The overall survival and relapse-free survival rates at 5 years were 94.7 and 51.4%, respectively </plain></SENT>
<SENT sid="15" pm="."><plain>Thus, salivary gland <z:hpo ids='HP_0002665'>lymphoma</z:hpo> proved to be an indolent disease </plain></SENT>
</text></document>